S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy

Inclusion Criteria: * Partial onset seizures, whether or not secondarily generalized; * at least 1 partial seizure and no more than 14 partial seizures per month as measured by historic baseline; * using 1, but no more than 2 concomitant marketed antiepileptic drugs (AEDs) at the time of study entry. Exclusion Criteria: * Presence of known pseudoseizures within the last year; * presence or history of allergy to the components of Keppra (levetiracetam, lactose, cornstarch, and excipients) or other pyrrolidine derivatives; * on felbamate with less than 18 months exposure; * on vigabatrin, but visual field had not been assessed as per recommendation of the manufacturer, i.e., every 6 months; * uncountable seizures (clusters) or history of convulsive status epilepticus within the last 5 years.